论文部分内容阅读
本刊讯(记者高军房志雄)2015年6月27日,浙江中医药大学宣布,我国具有自主知识产权的抗癌中药康莱特注射液在美顺利完成治疗胰腺癌的Ⅱ期临床试验,经美国FDA评审通过,将进入Ⅲ期临床,成为中国第一个在美国本土进入Ⅲ期临床的中药注射剂。相关方面称,这不仅是我国在中药创制专项研究上的一个重大突破,更是我国中药国际化道路上的一座新里程碑。康莱特注射液是由中国工程院院士、浙江中医药大学研究员李大鹏领衔的科研团队,运用超临界二氧化碳萃取等国际领先技术,从中药薏苡仁中提取分离
(Reporter Gao Jun Fang Zhixiong) June 27, 2015, Zhejiang University of Traditional Chinese Medicine announced that our country with independent intellectual property rights Kanglaite injection of anticancer Chinese medicine successfully completed the treatment of pancreatic cancer in the United States Phase Ⅱ clinical trials, the Approved by the US FDA, it will enter stage III clinical trials and become the first Chinese traditional medicine injection to enter Phase III clinical trials in the United States. Relevant parties said that this is not only a major breakthrough made by our country in the special study on the creation of traditional Chinese medicine, but also a new milestone on the road to the internationalization of Chinese traditional medicine. Kanglaite injection by the Chinese Academy of Engineering, Zhejiang University of Chinese Medicine researcher led by Li Dapeng research team, the use of supercritical carbon dioxide extraction and other leading international technology, extract from the Chinese Yiyiren